恒瑞医药：子公司HRS-1780片获批开展II/III期临床试验

财中社07-27

7月27日，恒瑞医药（600276/01276）发布公告，子公司山东盛迪医药有限公司近日收到国家药品监督管理局核准签发的HRS-1780片的《药物临床试验批准通知书》，将于近期开展II/III 期临床试验。　　HRS-1780片是盐皮质激素受体拮抗剂(MRA)，临床拟用于治疗未控制高血压或难治性高血压。MRA已被推荐作为标准治疗之外的首选药物来管理难治性高血压。同类选择性非甾体类MRA艾沙利酮在...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2654013011?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-27 16:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654013011","market":"sh","top_or_hot":-1,"title":"恒瑞医药：子公司HRS-1780片获批开展II/III期临床试验","media":"财中社","content":"<div>\n<p>7月27日，恒瑞医药（600276/01276）发布公告，子公司山东盛迪医药有限公司近日收到国家药品监督管理局核准签发的HRS-1780片的《药物临床试验批准通知书》，将于近期开展II/III 期临床试验。　　HRS-1780片是盐皮质激素受体拮抗剂(MRA)，临床拟用于治疗未控制高血压或难治性高血压。MRA已被推荐作为标准治疗之外的首选药物来管理难治性高血压。同类选择性非甾体类MRA艾沙利酮在...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202607273822155717.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药：子公司HRS-1780片获批开展II/III期临床试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药：子公司HRS-1780片获批开展II/III期临床试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-27 16:53 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202607273822155717.html><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月27日，恒瑞医药（600276/01276）发布公告，子公司山东盛迪医药有限公司近日收到国家药品监督管理局核准签发的HRS-1780片的《药物临床试验批准通知书》，将于近期开展II/III 期临床试验。　　HRS-1780片是盐皮质激素受体拮抗剂(MRA)，临床拟用于治疗未控制高血压或难治性高血压。MRA已被推荐作为标准治疗之外的首选药物来管理难治性高血压。同类选择性非甾体类MRA艾沙利酮在...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202607273822155717.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1781817850.SGD","symbol_name":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","start_time":0,"source_url":"http://finance.eastmoney.com/a/202607273822155717.html","article_id":"2654013011","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607273822155717.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2654013011","pubTimestamp":1785142380,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"7月27日，恒瑞医药（600276/01276）发布公告，子公司山东盛迪医药有限公司近日收到国家药品监督管理局核准签发的HRS-1780片的《药物临床试验批准通知书》，将于近期开展II/III期临床试验。HRS-1780片是盐皮质激素受体拮抗剂(MRA)，临床拟用于治疗未控制高血压或难治性高血压。MRA已被推荐作为标准治疗之外的首选药物来管理难治性高血压。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK0239":"医药制造","PSYK":"PSYK ETF","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK0183":"MSCI概念","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0188":"融资融券","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK0012":"证金概念","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK4134":"信息科技咨询与其它服务","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK0028":"国家队","BMED":"iShares Health Innovation Active ETF","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","01276":"恒瑞医药","BK1191":"制药","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK0060":"抗癌","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU0359201612.USD":"贝莱德中国基金A2","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","III":"信息服务","BK0196":"行业龙头","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","MDTX":"Corgi MediaTek 2x Daily ETF"},"translate_title":"Hengrui Medicine: Subsidiary HRS-1780 tablets approved for phase II/III clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"BMED":1.5,"PSYK":1.5,"01276":1.5,"IBBQ":1.5,"III":1.5,"MDTX":1.5,"IBBJ":1.5},"content_text":"7月27日，恒瑞医药（600276/01276）发布公告，子公司山东盛迪医药有限公司近日收到国家药品监督管理局核准签发的HRS-1780片的《药物临床试验批准通知书》，将于近期开展II/III 期临床试验。　　HRS-1780片是盐皮质激素受体拮抗剂(MRA)，临床拟用于治疗未控制高血压或难治性高血压。MRA已被推荐作为标准治疗之外的首选药物来管理难治性高血压。同类选择性非甾体类MRA艾沙利酮在日本上市用于高血压患者的治疗，国内尚无同类产品上市。　　目前，该项目有治疗慢性肾脏病、原发性醛固酮增多症的临床试验正在同步开发中，已推进至 II/III 期。截至目前，HRS-1780片相关项目累计研发投入约为1亿元(未经审计)。　　2026年一季度，恒瑞医药实现收入81.41亿元，归母净利润22.82亿元。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654013011","isCrawlerRequest":true}